Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug.
- 1 April 1982
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 65 (4) , 819-824
- https://doi.org/10.1161/01.cir.65.4.819
Abstract
Six patients are presented who developed pulmonary infiltrates of undetermined origin while being treated for severe ventricular arrhythmias with amiodarone hydrochloride. Biopsy material was available in four patients and revealed interstitial or alveolar fibrosis and pneumonitis. Four patients recovered and two died of severe cardiopulmonary decompensation; all of the patients who recovered received corticosteroid therapy. Pulmonary fibrosis is a previously unreported complication of amiodarone therapy.This publication has 8 references indexed in Scilit:
- Possible association of pneumonitis with amiodarone therapyAmerican Heart Journal, 1980
- Control of refractory cardiac arrhythmias with amiodaroneArchives of internal medicine (1960), 1979
- Clinical trial of amiodarone hydrochloride for the treatment of refractory arrhythmiasThe American Journal of Cardiology, 1979
- New antiarrhythmic agents: Amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamilThe American Journal of Cardiology, 1978
- Clinical efficacy of amiodarone as an antiarrhythmic agentThe American Journal of Cardiology, 1976
- Effect of amiodarone in the Wolff-Parkinson-White syndromeThe American Journal of Cardiology, 1976
- Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochlorideThe American Journal of Cardiology, 1974